IL1B

Interleukin-1 beta

Score: 0.648 Price: $0.65 Medium Druggability Status: active Wiki: IL1B

🔥 Neuroinflammation 🧠 Neurodegeneration

HYPOTHESES

3

PAPERS

0

KG EDGES

817

DEBATES

1

3D Protein Structure

🧬 IL1B — PDB 1I1B Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

Medium

Score: 0.49

Clinical Stage

Approved

Target Class

Ligand

Safety

0.60

Druggability Analysis

Drug Development0.60

Structural Tractability0.85

Target Class0.50

Safety Profile0.60

Key Metrics

PDB Structures:

49

Known Drugs:

2

Approved:

0

In Clinical Trials:

0

Drug Pipeline (2 compounds)

Druggability Rationale: This ligand/growth factor has druggable receptor-binding interfaces amenable to neutralizing antibodies, decoy receptors, or small molecule antagonists. Crystal structures available (49 PDB entries) supporting structure-based drug design. AlphaFold predicted structure available for computational screening.

Mechanism: IL-1 receptor antagonist or neutralizing monoclonal antibody

Drug Pipeline (2 compounds)

Known Drugs:

Anakinra (Approved) — Rheumatoid arthritis

Canakinumab (Approved) — Systemic inflammatory diseases

Structural Data:

PDB (49) ✓AlphaFold ✓Cryo-EM —

1S0L 1T4Q 1TOO 1TP0 1TWE+44 more

UniProt: O43645

🧬 3D Protein Structure

🧬 IL1B — PDB 1I1B Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

Selectivity is assessed at the receptor level. Ligand traps may cross-react with related growth factors sharing receptor subunits.

3D Protein Structure

PDB: Open in RCSB AlphaFold model

Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.

Clinical Trials (8)

Relevant trials from ClinicalTrials.gov

Active

1

Completed

7

Total Enrollment

292

By Phase

PHASE1: 1 · PHASE2: 6 · PHASE3: 1

Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA Active Not Recruiting

PHASE1 NCT04798339 n=13

Myelodysplastic Syndromes

Interventions: Canakinumab Injection, Darbepoetin Alfa

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Started: 2021-03-30

An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes Completed

PHASE3 NCT02911857 n=4

Periodic Fevers Syndrome

Interventions: Canakinumab (AIN457)

Sponsor: Novartis Pharmaceuticals | Started: 2016-10-03

Safety and Tolerability of Anakinra in Combination With Riluzol in Amyotrophic Lateral Sclerosis Completed

PHASE2 NCT01277315 n=20

Amyotrophic Lateral Sclerosis (ALS)

Interventions: Anakinra

Sponsor: Charite University, Berlin, Germany | Started: 2011-02

Juvenile Rheumatoid Arthritis Completed

PHASE2 NCT00037648 n=86

Juvenile Chronic Arthritis

Interventions: Anakinra, Placebo

Sponsor: Amgen | Started: 2000-07

Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis Completed

PHASE2 NCT01809132 n=104

Acute Alcoholic Hepatitis

Interventions: Anakinra, Pentoxifylline, Zinc Sulfate

Sponsor: Mack Mitchell | Started: 2013-09

Canakinumab for Pyoderma Gangrenosum Completed

PHASE2 NCT01302795 n=5

Pyoderma Gangrenosum

Interventions: Canakinumab

Sponsor: University of Zurich | Started: 2011-02

Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Completed

PHASE2 NCT01148797 n=15

Colchicine Resistant/Intolerant Familial

Interventions: Canakinumab

Sponsor: Novartis Pharmaceuticals | Started: 2010-12

Canakinumab in Covid-19 Cardiac Injury (The Three C Study) Completed

PHASE2 NCT04365153 n=45

COVID-19, SARS-CoV 2

Interventions: Canakinumab Injection 600mg, Canakinumab Injection 300mg, Placebos

Sponsor: The Cleveland Clinic | Started: 2020-04-24

Linked Hypotheses (1)

Peripheral-to-Central Inflammation Circuit Breaker0.626

Linked Experiments (0)

No linked experiments

Scoring Dimensions

Knowledge Graph (20)

associated with (1)

IL1B→neurodegeneration

co discussed (13)

MMP9→IL1BSLC7A11→IL1BCGAS→IL1BAQP4→IL1BCD38→IL1B

▸ Show 8 more

C1Q→IL1BNAMPT→IL1BGPX4→IL1BPLA2G6→IL1BIL1B→MMP2IL1B→DNASE2IL1B→STING1IL1B→C3

interacts with (6)

NLRP3→IL1BCASP1→IL1BIL1B→NLRP3IL1B→CASP1IL1B→PYCARD

▸ Show 1 more

Debate History (1)

Should IL1B (Interleukin-1 beta) be prioritized as a therapeutic target for neur2026-04-21